BioAlliance Pharma SA: Quarterly information as of September 30, 2012

Regulatory News:

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, today publishes the major key milestones achieved during the third quarter of 2012.

Two key achievements will reinforce the Company’s capacity to create value:

In parallel, BioAlliance Pharma has pursued the registration procedure of Sitavig in the US and in Europe for the treatment of recurrent labial herpes, as well as the recruitment of patients in its Phase II clinical trial with Validive in the radio or chemotherapy-induced oral mucositis in patients with head and neck cancer. The Company has also obtained the regulatory authorizations to start its Phase I/II trial with Amep in the metastatic melanoma.

reminds Judith Greciet, CEO of BioAlliance Pharma.

While awaiting the commercialization of Oravig in the United-States, the turnover for Q3 2012 amounted to €279,000, representing the royalties on Loramyc sales in Europe by our partner Therabel, as well as the staggering of the payments received under the Asian license agreements.

The consolidated cash reserves stood at €17.3 million as of September 30, 2012, enabling BioAlliance Pharma to pursue as planned its ongoing development activities. Non conditional payments expected from our partners Therabel and Vestiq should reinforce the Company’s resources within the next months.

* * *

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Loramyc/Oravig (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)Sitavir/Sitavig (Acyclovir Lauriad) (labialis herpes): Positive phase III final results; registration statusFentanyl Lauriad (chronic cancer pain): Positive preliminary Phase I results

Livatag (Doxorubicin Transdrug™) (primary liver cancer): Phase III on goingValidive (Clonidine Lauriad) (mucositis): Phase II on goingAMEP (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.